These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6754931)

  • 1. Lipoproteins as potential site-specific delivery systems for diagnostic and therapeutic agents.
    Counsell RE; Pohland RC
    J Med Chem; 1982 Oct; 25(10):1115-20. PubMed ID: 6754931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoproteins as carriers for organ-imaging radiopharmaceuticals.
    Counsell RE; Schwendner SW; DeForge LE; DeGalan MR; Newton RS
    Targeted Diagn Ther; 1991; 5():251-314. PubMed ID: 1797169
    [No Abstract]   [Full Text] [Related]  

  • 3. Plasma lipoproteins as drug carriers: pharmacological activity and disposition of the complex of beta-sitosteryl-beta-D-glucopyranoside with plasma lipoproteins.
    Seki J; Okita A; Watanabe M; Nakagawa T; Honda K; Tatewaki N; Sugiyama M
    J Pharm Sci; 1985 Dec; 74(12):1259-64. PubMed ID: 4087191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VLDL/LDL acts as a drug carrier and regulates the transport and metabolism of drugs in the body.
    Yamamoto H; Takada T; Yamanashi Y; Ogura M; Masuo Y; Harada-Shiba M; Suzuki H
    Sci Rep; 2017 Apr; 7(1):633. PubMed ID: 28377633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of plasma lipoproteins in modifying the toxic effects of water-insoluble drugs: studies with cyclosporine A.
    Wasan KM; Ramaswamy M; Kwong M; Boulanger KD
    AAPS PharmSci; 2002; 4(4):E30. PubMed ID: 12646002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible implications in the use of exogenous phospholipids.
    Gregoriadis G; Siliprandi N; Turchetto E
    Life Sci; 1977 Jun; 20(11):1773-85. PubMed ID: 327178
    [No Abstract]   [Full Text] [Related]  

  • 7. Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake.
    Chung NS; Wasan KM
    Adv Drug Deliv Rev; 2004 May; 56(9):1315-34. PubMed ID: 15109771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
    Dahan A; Hoffman A
    J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A reappraisal of the mechanisms of hypocholesterolemic action of therapeutic agents.
    Sodhi HS; Kudchodkar BJ; Clifford C; Borhani N; Mason DT
    Adv Exp Med Biol; 1978; 109():331-45. PubMed ID: 364950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-specific ligands for selective drug delivery to tissues and organs.
    Ponpipom MM; Bugianesi RL; Robbins JC; Doebber TW; Shen TY
    J Med Chem; 1981 Dec; 24(12):1388-95. PubMed ID: 7310815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Extracellular Binding Proteins in the Cellular Uptake of Drugs: Impact on Quantitative In Vitro-to-In Vivo Extrapolations of Toxicity and Efficacy in Physiologically Based Pharmacokinetic-Pharmacodynamic Research.
    Poulin P; Burczynski FJ; Haddad S
    J Pharm Sci; 2016 Feb; 105(2):497-508. PubMed ID: 26173749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery.
    Sakagami M
    Adv Drug Deliv Rev; 2006 Oct; 58(9-10):1030-60. PubMed ID: 17010473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Structure and metabolism of lipoproteins].
    Beucler I; Salmon S; Petit E; Ayrault-Jarrier M; Polonovski J
    Ann Biol Clin (Paris); 1986; 44(5):531-5. PubMed ID: 3544976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of spin-labeled clofibrate to lipoproteins.
    Olivier JL; Chachaty C; Wolf C; Salmon S; Bereziat G
    Biochim Biophys Acta; 1988 Dec; 963(3):515-24. PubMed ID: 2848587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local controlled drug delivery to the brain: mathematical modeling of the underlying mass transport mechanisms.
    Siepmann J; Siepmann F; Florence AT
    Int J Pharm; 2006 May; 314(2):101-19. PubMed ID: 16647231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiological transport forces govern drug distribution for stent-based delivery.
    Hwang CW; Wu D; Edelman ER
    Circulation; 2001 Jul; 104(5):600-5. PubMed ID: 11479260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of hepatic lipoprotein receptors in the dog. Rapid regulation of apolipoprotein B,E receptors, but not of apolipoprotein E receptors, by intestinal lipoproteins and bile acids.
    Angelin B; Raviola CA; Innerarity TL; Mahley RW
    J Clin Invest; 1983 Apr; 71(4):816-31. PubMed ID: 6300188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Frontiers in Drug Delivery.
    Tibbitt MW; Dahlman JE; Langer R
    J Am Chem Soc; 2016 Jan; 138(3):704-17. PubMed ID: 26741786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery.
    Wasan KM; Brocks DR; Lee SD; Sachs-Barrable K; Thornton SJ
    Nat Rev Drug Discov; 2008 Jan; 7(1):84-99. PubMed ID: 18079757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rectal drug administration: clinical pharmacokinetic considerations.
    de Boer AG; Moolenaar F; de Leede LG; Breimer DD
    Clin Pharmacokinet; 1982; 7(4):285-311. PubMed ID: 6126289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.